A new era in cancer treatment has begun, offering a beacon of hope and a significant reduction in treatment time for thousands of patients across England. Shirley Xerxes and Stephen Friend are among the first to experience this innovative approach, receiving a new injection form of the immunotherapy drug pembrolizumab.
Shirley, undergoing treatment at the Mount Vernon Cancer Centre, described the experience as “wonderful.” She appreciated the kindness of the nursing staff and the convenience of the injection, administered quickly into her abdomen. For Shirley, the newfound time means more moments dedicated to her beloved garden, especially with the arrival of spring.
Stephen Friend, 67, battling melanoma, echoed this sentiment, emphasizing the stress reduction this new method provides. Having previously enjoyed excellent health and limited interaction with the NHS, he found the entire process “amazing.” The shift promises a more streamlined experience for patients like Stephen.
Traditionally, pembrolizumab required careful preparation by hospital pharmacy teams, involving sterile intravenous bags and a time-consuming process. This new ready-to-use injection bypasses those steps, freeing up valuable time for dedicated NHS staff.
Approximately 14,000 patients initiate pembrolizumab therapy annually in England, and a large majority are expected to transition to this injection format. Treatment schedules will vary, with injections lasting either one minute every three weeks or two minutes every six weeks, tailored to the specific cancer type.
Vikash Dodhia, head of pharmacy at Mount Vernon, revealed that Shirley was potentially the very first patient in the country to receive this particular treatment. He highlighted the dramatic difference in volume – a mere 4ml, less than a teaspoon, compared to the previous 100ml intravenous drip, which could take up to 45 minutes to administer.
This reduction in treatment time isn’t just a benefit for patients; it directly translates to increased capacity for healthcare professionals. Faster administration means more patients can be treated within the same timeframe, potentially accelerating access to vital care. The sooner treatment begins, the greater the potential benefit for cancer patients.
The drug itself, pembrolizumab, functions by releasing the brakes on the body’s immune system, enabling it to recognize and attack cancer cells. Analysis from the manufacturer suggests a 44% reduction in staff time dedicated to treatment preparation with the new injection method.
Experts emphasize that this innovation isn’t just about convenience; it’s about maximizing the impact of cancer care. Reducing the burden of treatment and hospital visits can significantly improve a patient’s quality of life, while simultaneously allowing NHS teams to treat more individuals and reduce waiting times.
